Latest Unigene Labs Inc (UGNEQ) Headlines Post Me
Post# of 4
Posted On: 03/11/2014 11:09:00 PM
Latest Unigene Labs Inc (UGNEQ) Headlines
Post Menopausal Osteoporosis - Pipeline Review, H2 2013 Complete With Latest Updates, and Special Features on Late-Stage and Discontinued Projects
M2 - Tue Nov 05, 9:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/ctcqv3/post_menopausal) has announced the addition of the "Post Menopausal Osteoporosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Post Menopausal Osteoporosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Post Menopausal Osteoporosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Post Menopausal Osteoporosis. Post Menopausal Osteoporosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Post Menopausal Osteoporosis. - A review of the Post Menopausal Osteoporosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Post Menopausal Osteoporosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Amgen Inc. - Merck & Co., Inc. - Pfizer Inc. - Zydus Cadila Healthcare Limited - Osteologix, Inc. - Unigene Laboratories, Inc. - Radius Health, Inc. For more information visit http://www.researchandmarkets.com/research/ct...menopausal About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Enteris BioPharma Initiates Business and Development Activities Targeting Oral Delivery of Peptides and Small Molecule Therapeutics
PR Newswire - Mon Aug 05, 7:01AM CDT
Enteris BioPharma, Inc., an industry leader in innovative oral dosage formulations, today announced the official launch of its business, operational and development activities as the Company unveils enhancements to its clinically proven oral peptide delivery platform, Peptelligence(TM), that extend the technology to small molecule therapeutics. Enteris recently acquired the Peptelligence(TM) platform, along with proven nasal delivery technology and a recombinant manufacturing process for therapeutically relevant peptides, from Unigene Laboratories, Inc.
Post Menopausal Osteoporosis - Pipeline Review, H2 2013 Complete With Latest Updates, and Special Features on Late-Stage and Discontinued Projects
M2 - Tue Nov 05, 9:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/ctcqv3/post_menopausal) has announced the addition of the "Post Menopausal Osteoporosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Post Menopausal Osteoporosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Post Menopausal Osteoporosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Post Menopausal Osteoporosis. Post Menopausal Osteoporosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Post Menopausal Osteoporosis. - A review of the Post Menopausal Osteoporosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Post Menopausal Osteoporosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Amgen Inc. - Merck & Co., Inc. - Pfizer Inc. - Zydus Cadila Healthcare Limited - Osteologix, Inc. - Unigene Laboratories, Inc. - Radius Health, Inc. For more information visit http://www.researchandmarkets.com/research/ct...menopausal About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Enteris BioPharma Initiates Business and Development Activities Targeting Oral Delivery of Peptides and Small Molecule Therapeutics
PR Newswire - Mon Aug 05, 7:01AM CDT
Enteris BioPharma, Inc., an industry leader in innovative oral dosage formulations, today announced the official launch of its business, operational and development activities as the Company unveils enhancements to its clinically proven oral peptide delivery platform, Peptelligence(TM), that extend the technology to small molecule therapeutics. Enteris recently acquired the Peptelligence(TM) platform, along with proven nasal delivery technology and a recombinant manufacturing process for therapeutically relevant peptides, from Unigene Laboratories, Inc.
(0)
(0)